77 related articles for article (PubMed ID: 28558940)
21. Enhanced proteotoxic stress: one of the contributors for hyperthermic potentiation of the proteasome inhibitor bortezomib using magnetic nanoparticles.
Alvarez-Berrios MP; Castillo A; Merida F; Mendez J; Rinaldi C; Torres-Lugo M
Biomater Sci; 2015 Feb; 3(2):391-400. PubMed ID: 26218130
[TBL] [Abstract][Full Text] [Related]
22. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
Horton TM; Gannavarapu A; Blaney SM; D'Argenio DZ; Plon SE; Berg SL
Cancer Chemother Pharmacol; 2006 Jul; 58(1):13-23. PubMed ID: 16292537
[TBL] [Abstract][Full Text] [Related]
23. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma.
Bao X; Ren T; Huang Y; Ren C; Yang K; Zhang H; Guo W
Int J Oncol; 2017 Feb; 50(2):477-486. PubMed ID: 28000897
[TBL] [Abstract][Full Text] [Related]
25. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
[TBL] [Abstract][Full Text] [Related]
26. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.
Ottosson-Wadlund A; Ceder R; Preta G; Pokrovskaja K; Grafström RC; Heyman M; Söderhäll S; Grandér D; Hedenfalk I; Robertson JD; Fadeel B
Mol Pharmacol; 2013 Jan; 83(1):245-55. PubMed ID: 23093495
[TBL] [Abstract][Full Text] [Related]
27. Apoptotic and genotoxic effects of low-intensity ultrasound on healthy and leukemic human peripheral mononuclear blood cells.
Saliev T; Begimbetova D; Baiskhanova D; Abetov D; Kairov U; Gilman CP; Matkarimov B; Tachibana K
J Med Ultrason (2001); 2018 Jan; 45(1):31-39. PubMed ID: 28689300
[TBL] [Abstract][Full Text] [Related]
28. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
29. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
[TBL] [Abstract][Full Text] [Related]
30. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
31. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.
Cacan E; Spring AM; Kumari A; Greer SF; Garnett-Benson C
Int J Mol Sci; 2015 Dec; 16(12):30405-21. PubMed ID: 26703577
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate.
Mpakou V; Papadavid E; Kontsioti F; Konsta E; Vikentiou M; Spathis A; Papageorgiou S; Vasilatou D; Gkontopoulos K; Mpazani E; Karakitsos P; Rigopoulos D; Dimitriadis G; Pappa V
PLoS One; 2017; 12(1):e0170186. PubMed ID: 28107479
[TBL] [Abstract][Full Text] [Related]
33. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
[TBL] [Abstract][Full Text] [Related]
34. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib sensitizes human glioblastoma cells to induction of apoptosis by type I interferons through NOXA expression and Mcl-1 cleavage.
Wang R; Davidoff AM; Pfeffer LM
Biochem Biophys Res Commun; 2016 Sep; 478(1):128-134. PubMed ID: 27450810
[TBL] [Abstract][Full Text] [Related]
36. Endoplasmic reticulum stress and autophagy participate in apoptosis induced by bortezomib in cervical cancer cells.
Zhang Y; Bai C; Lu D; Wu X; Gao L; Zhang W
Biotechnol Lett; 2016 Feb; 38(2):357-65. PubMed ID: 26423802
[TBL] [Abstract][Full Text] [Related]
37. Atg3 Overexpression Enhances Bortezomib-Induced Cell Death in SKM-1 Cell.
Zhuang L; Ma Y; Wang Q; Zhang J; Zhu C; Zhang L; Xu X
PLoS One; 2016; 11(7):e0158761. PubMed ID: 27391105
[TBL] [Abstract][Full Text] [Related]
38. Modification of thermosensitivity by amrubicin or amrubicinol in human lung adenocarcinoma A549 cells and the kinetics of apoptosis and necrosis induction.
Hayashi S; Hatashita M; Matsumoto H; Jin ZH; Shioura H; Kano E
Int J Mol Med; 2005 Sep; 16(3):381-7. PubMed ID: 16077943
[TBL] [Abstract][Full Text] [Related]
39. The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Cosenza M; Civallero M; Pozzi S; Marcheselli L; Bari A; Sacchi S
Hematol Oncol; 2015 Dec; 33(4):166-75. PubMed ID: 25394177
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.
Lin L; Chen D; Xiang ZF; Pei RZ; Zhang PS; Liu XH; Du XH; Lu Y
Cancer Biomark; 2017 Aug; 20(2):217-224. PubMed ID: 28869453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
